Looking for the next apple? This is the orchard.
|
|
|
|
Utility companies and their respective stocks can provide investors with a low-risk investment and unique advantage. Income investors can purchase smallcap utility company stocks, which are often undervalued and can provide long-term gains. Utility stocks tend to be lower risk and, much like conservative investments such as bonds, allow investors to take advantage of their higher dividend payouts.
|
|
|
|
|
Tuesday, September 3, 2019
QuoteMedia, based in Fountain Hills, Arizona, provides cloud-based financial data, market news feeds, and financial software solutions. Its customers include financial service companies, online brokerages, clearing firms, banks, media portals, public corporations and individual investors. The company provides a single source solution providing products such as streaming quotes, charting, historical data, technical analysis, news and research. Information can customized and provided to multiple platforms including terminals and mobile devices.
Michael Kupinski, DOR, Senior Research Analyst, Noble Capital Markets, Inc.
Refer to full report for price target, fundamental analysis and rating.
Get full report on Channelchek desktop.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst
certification and important disclosures included in full report.
NOTE: investment decisions should not be based upon the content of
this research summary. Proper due diligence is required before
making any investment decision.
|
|
|
|
|
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, today announced anticipated milestones and future guidance on its clinical development programs, manufacturing and strategy for bringing its lead drug candidate, Oncoprex™ immunogene therapy, to market.
These anticipated milestones and future guidance are incorporated into the latest update of the company’s corporate presentation, which can be found on the company’s website.
“These milestones emphasize our commitment to developing potentially life-changing gene technologies for cancer patients who need them most,” said Rodney Varner, Chairman and Chief Executive Officer of Genprex. “We continue to dedicate our efforts toward developing Oncoprex for non-small cell lung cancer (“NSCLC”) and we believe that achievement of these milestones will enable us to advance our gene therapy platform and position us to bring our drug candidate to commercialization.”
Anticipated milestones and future guidance:
2H 2019
1H 2020
In addition to the milestone updates, Genprex also unveiled in its updated corporate presentation, an overview of the limitations to current NSCLC treatment and a swimmer plot demonstrating results to date of its Phase I/II clinical trial administering Oncoprex in combination with erlotinib against NSCLC. Genprex also recently launched a new interactive timeline on its website where visitors can follow the company’s success since its inception.
About Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. For more information, please visit the company’s web site at www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding our stated milestones and our ability to advance the clinical development, manufacturing and commercialization of our product candidates, and the effects of Oncoprex on cancer. Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements include our ability to achieve our stated milestones, the timing and effect of our achieving those milestones, and of other factors, on the clinical development, manufacturing and commercialization of our product candidates, the presence and level of TUSC2’s effect on cancer, the timing and success of our clinical trials and planned clinical trials of TUSC2 and Oncoprex™ and our other potential product candidates and the timing and success of obtaining FDA approval of Oncoprex™ and our other potential product candidates. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190903005044/en/
Genprex,
Inc.
(877) 774-GNPX (4679)
Investor
Relations
GNPX Investor Relations
(877) 774-GNPX (4679) ext. #2
[email protected]
Media
Contact
Genprex Media Relations
Kalyn Dabbs
(877) 774-GNPX (4679) ext. #3
[email protected]
Copyright Business Wire 2019
News
Provided by Business Wire via QuoteMedia
|
|
|
|
|
Company
to showcase its innovative Alzheimer’s, Parkinson’s and ALS programs
TORONTO and CAMBRIDGE, MA, Sept. 3, 2019 /PRNewswire/ – ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced its participation in the 21st Annual Global Investment Conference sponsored by H.C. Wainwright & Co. LLC. The conference is being held September 8-10, 2019 at the New York Palace Hotel in New York.
ProMIS’ Executive Chairman, Eugene Williams will provide overviews of its novel drug discovery and development programs for Alzheimer’s disease, Parkinson’s disease and ALS (amyotrophic lateral sclerosis) Tuesday, September 10th at 10:25 am ET. The audio webcast and slides of Mr. Williams’ presentation will be archived and available on ProMIS’ web site and through the following link http://wsw.com/webcast/hcw5/arfxf/.
About ProMIS’ Platform
Technology
Numerous studies show that a common root cause of neurodegenerative diseases is the toxic oligomer, a misfolded protein that derives from naturally occurring proteins in the brain. Using its novel drug discovery platform, ProMIS can uniquely and selectively target the toxic oligomer, filling a critical gap for drug developers as traditional approaches to developing antibodies are unable to isolate and target the toxic oligomer with adequate precision. This proprietary platform can identify targets to produce, test and advance antibody candidates quickly and cost-effectively. ProMIS’ lead candidate antibody, PMN310 for Alzheimer’s disease (AD), demonstrates a high degree of binding to toxic oligomers without binding to non-toxic forms of naturally occurring amyloid beta protein. The company’s program for Parkinson’s disease (PD) is based on the development of several potential antibody therapeutic candidates aimed at selectively targeting toxic oligomers of the protein ?-synuclein, considered a root cause of PD. Similarly, ProMIS has identified antibody candidates selectively targeting toxic oligomers of the protein TDP43, considered a root cause of ALS.
About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery platform is based on the use of two complementary thermodynamic, computational discovery engines – ProMIS and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.
To learn more, visit us at www.promisneurosciences.com, follow us on Twitter and LinkedIn and listen to the podcast, Saving Minds, at iTunes or Spotify.
The TSX has not reviewed and
does not accept responsibility for the adequacy or accuracy of this release.
This information release contains certain forward-looking information. Such
information involves known and unknown risks, uncertainties and other factors
that may cause actual results, performance or achievements to be materially
different from those implied by statements herein, and therefore these
statements should not be read as guarantees of future performance or results.
All forward-looking statements are based on the Company’s current beliefs as
well as assumptions made by and information currently available to it as well
as other factors. Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this press
release. Due to risks and uncertainties, including the risks and uncertainties
identified by the Company in its public securities filings, actual events may
differ materially from current expectations. The Company disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
View original content to download multimedia:http://www.prnewswire.com/news-releases/promis-neurosciences-to-present-at-hc-wainwright-investment-conference-300909802.html
SOURCE ProMIS Neurosciences Inc.
News Provided by PR Newswire via QuoteMedia
|
|
|
|
|
(Note: companies that could be impacted by the content of this article are listed at the base of the story (desktop version). This article uses third-party references to provide a bullish, bearish and balanced point of view; sources listed in the “Balanced” section)
Investing in precious metals is a good way for any investor to diversify their portfolio. Precious metals, to most, primarily mean platinum, silver, and gold. From an investor standpoint, gold and silver are typically the top two choices. With silver, investors need to remember that the price is driven by market demand, and, just like gold, investors typically flock to silver for long-term holds. In comparison, however, silver is more volatile than gold but still considered a safe investment.
|
|
|
|
|
Friday, August 30, 2019
Aurania Resources Ltd. is a junior mining exploration company engaged in the identification, evaluation, acquisition, and exploration of mineral property interests, with a focus on precious metals and copper. Its flagship asset, The Lost Cities – Cutucu Project, is in southeastern Ecuador in the Province of Morona-Santiago. The project includes 42 mineral exploration concessions encompassing an area of approximately 208,000 hectares, or 2,080 square kilometers. The company’s common shares are traded on the TSX Venture Exchange under the symbol “ARU”, the OTCQB Venture Market under the symbol “AUIAF” and on the Frankfurt Exchange under the symbol “20Q”.
Mark Reichman, Senior Research Analyst, Noble Capital Markets, Inc.
Refer to full report for price target, fundamental analysis and rating.
Get full report on Channelchek desktop.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst
certification and important disclosures included in full report.
NOTE: investment decisions should not be based upon the content of
this research summary. Proper due diligence is required before
making any investment decision.
|
|
|
|
|
A United-States-made capital goods shipments slowdown in the early third-quarter points to business investment troubles. Although new orders rose in July, shipments fell the most in nearly three years, indicating a continued decline in economic growth. Business investment contracted in the second quarter for the first time since 2016. According to Jerome Powell, uncertainty in trade policy could be playing a role in the decline of capital spending.
|
|
|
|
|
The mention of investing in small & microcap stocks may initially raise some red flags. However, one must remember that any investment carries a great deal of risk and uncertainty, but the prepared investor will do the research and make a sound decision for their portfolio. A smallcap stock typically has a market cap of $300 million to $2 billion, while a microcap company falls in the $50 million to $300 million range. Although these smaller-scaled companies are viewed as young and volatile, they also bring many potential investment benefits.
|
|
|
|
|
Blockchain technologies can present new possibilities and help accelerate the process of the agriculture industry by improving both supply chain management and financial transactions for farmers. These improved supply chain management and the financial process can benefit the agriculture industry on all scales, providing plenty of future value to both farmers and consumers. The development and implementation of new technologies into the agricultural industry can drive both social and commercial causes.
|
|
|
|
|
When the news broke in August about the 10% tariff on $300 billion of Chinese goods, shipping stocks saw a downturn. Unfortunately, small & microcap stocks took the biggest hit due to their size and structure. Most of these companies are not equipped to take a hit that large. Between the dispute among China and the US, the stock prices across the industry fluctuated. Although this sounds all bad, that is not the case. Not all shipping stocks are the same and many cater to different clients outside of China.
|
|
|
|
|
Last July, US President Donald Trump imposed a large number of tariffs on China, hoping to strike up a deal for better trade practices. So far, the US has implemented tariffs on $250 billion of Chinese products and China has responded with about $185 billion on US goods. At this point, neither side is willing to back down, and many industries are starting to feel the effects. As trade has been the biggest sector affected, airlines are planning for lowered overall profits.
|
|
|
|
|
|
1 minute preview above. Click below to listen to the full episode. |
|
The Idea: Become a Star, Built on “Terminal Goodlookingness:” Meet Rob Lowe. |
|
This Hollywood icon landed his first TV role at age 15 and came to prominence as a teen idol and member of the Brat Pack with roles in films like The Outsiders and Oxford Blues. Find out from this insightful American actor how making a business out of being in “the business” is no easy road. GUEST:
Following numerous television roles in the early 1980s, Rob Lowe came to prominence as a teen idol and member of the Brat Pack, with roles in films like The Outsiders (1983), Class (1983), The Hotel New Hampshire (1984), Oxford Blues (1984), St. Elmo’s Fire (1985), About Last Night… (1986), and Square Dance (1987). The success of these films established him as a Hollywood A-lister. Every year for the last 20 years, Lowe has been in a television series, including hits like The West Wing, Parks and Recreation, Brothers and Sisters, and Code Black. In this deeply personal and inspirational episode of the IPO podcast series, Rob tells it like it is and how it was to make a business out of being in “The Business.”
Running time 49:29 – contains some explicit language
HIGHLIGHTS:
14:15 – Interview with Mr. Lowe
15:14 – “I have terminal goodlookingness; it’s untreatable.”
41:30 – “Early in my career I was offered $1 million for one day’s work to do a coffee commercial… and they convinced me to turn it down.”
HOST:
Brant Pinvidic, Hollywood producer and director (Bar Rescue, Biggest loser), C-level corporate consultant, columnist for Forbes and author (3-Minute Rule – Penguin Random House, October 2019). The most innovative Ideas, the inspirational People behind them, and the wealth of Opportunities they create… that’s IPO from Channelchek. |
|
watch the IPO series trailer
|
|
|
|
|
|
Wednesday, August 28, 2019
One Stop Systems designs, manufactures, and markets high-end systems for high performance computing applications. The Company combines state-of-the art components from major technology providers to design and manufacture purpose-built systems that allow customers to exploit Big Data opportunities faster and more efficiently. HPC applications require ultra-fast processing power and the ability to quickly access and store ever-growing data sets. OSS is uniquely positioned as a specialized provider for the high-end of this marketplace providing custom servers, compute accelerators, solid-state storage arrays, and system expansion systems.
Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.
Refer to full report for price target, fundamental analysis and rating.
Get full report on Channelchek desktop.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst
certification and important disclosures included in full report.
NOTE: investment decisions should not be based upon the content of
this research summary. Proper due diligence is required before
making any investment decision.